All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

For four decades, Ohio State blood and bone marrow transplant innovation has improved cancer care with an increasing emphasis ...

Very sick patients who get a bone marrow transplant at Medical University of South Carolina survive at a much higher rate ...

Megakaryocytes form a three-dimensional (3D) cage composed of laminin and collagen IV connected to the basement membrane surrounding them. This microarchitecture stabilizes megakaryocytes within their ...

Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to macrophage-based therapies, and clues behind why ...

Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...

A novel drug regimen tested for the first time by researchers at Fred Hutch Cancer Center has shown great promise in ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...